All OpportunitiesView on Grants.gov
HHS-FDA
FOR-FD-26-004
discretionary
Forecasted
Novel approaches to support therapeutic development in ultra-rare cancers
Food and Drug AdministrationPosted August 4, 2025
Official Federal Notice
View the complete notice on Grants.gov
Summary
The purpose of this program is to support new approaches that can be applied to facilitate therapeutic development in ultra-rare pediatric and adult cancers, including molecularly-defined subsets of more common cancers.
Specific areas of interest include, but are not limited to, the following examples:
• Development of infrastructure for a coordination network and data repository for patient-level data across institutions and internationally to support drug development and regulatory decision-making for one or more ultra-rare cancers.
• Investigations to explore opportunities to develop...
Read full notice on Grants.govEligible Applicants
- Independent school districts
- State governments
- Nonprofits (non-501(c)(3))
- Federally recognized tribal governments
- County governments
- Public institutions of higher education
- For-profit organizations
- Other tribal organizations
- Small businesses
- Nonprofits (501(c)(3))
- Public And Indian Housing Authorities
- Special district governments
- Private institutions of higher education
- City or township governments
Assistance Listings
93.103
Food and Drug Administration ResearchFunding Instrument
Cooperative Agreement
CFDA / Assistance Listing Numbers
93.103
Topics
Program Contact
Information on this page is sourced from official federal notices on Grants.gov. Always verify eligibility, deadlines, and requirements using the official notice. Funding Radar is not affiliated with the U.S. government.
Key Details
Expected Awards
2
Posted
August 4, 2025
Cost Sharing
Not Required
Agency
HHS-FDA
Data from Grants.gov
Last fetched: 3/23/2026